PARP12

Protein mono-ADP-ribosyltransferase PARP12 · Q9H0J9 · PARP12 on Sugi Atlas →

9,441 patent compounds predicted against PARP12, 7,318 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL524411	0.68	2/20
SCHEMBL78550	0.68	2/20
SCHEMBL527292	0.63	2/20
SCHEMBL525041	0.60	2/20
Pj34 (SCHEMBL422317)	1.00	1/20
Veliparib (SCHEMBL422318)	1.00	1/20
Veliparib (SCHEMBL422319)	1.00	1/20
Veliparib (SCHEMBL422320)	1.00	1/20
Olaparib (SCHEMBL426568)	1.00	1/20
Rucaparib (SCHEMBL844585)	1.00	1/20
Niraparib (SCHEMBL1421875)	1.00	1/20
Niraparib (SCHEMBL1421952)	1.00	1/20
Niraparib (SCHEMBL1422151)	1.00	1/20
Veliparib (SCHEMBL5511373)	1.00	1/20
Niraparib (SCHEMBL567839)	0.98	1/20
Niraparib (SCHEMBL567840)	0.98	1/20
Niraparib (SCHEMBL1422061)	0.98	1/20
Veliparib (SCHEMBL2368883)	0.98	1/20
Veliparib (SCHEMBL2368887)	0.98	1/20
Veliparib (SCHEMBL2368889)	0.98	1/20

Clinical trials — most relevant to PARP12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer	PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer	PHASE1	COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PARP12 binder may also engage these)

Protein	Name	Similarity
Q8BZ20	—	0.993	Q8BZ20 →
PARP4	Protein mono-ADP-ribosyltransferase PARP4	0.971	landscape →
E9PYK3	—	0.970	E9PYK3 →
Q9D2Q2	—	0.969	Q9D2Q2 →
Q14CH1	—	0.968	Q14CH1 →
Q6DCD7	—	0.967	Q6DCD7 →
P61800	—	0.966	P61800 →
P47823	—	0.965	P47823 →
Q9UGR2	—	0.965	Q9UGR2 →
Q5T7W7	—	0.965	Q5T7W7 →
Q5RJK3	—	0.965	Q5RJK3 →
Q7TQC5	—	0.965	Q7TQC5 →
Q3U269	—	0.964	Q3U269 →
Q5RF77	—	0.964	Q5RF77 →
Q3ULW8	—	0.964	Q3ULW8 →
ZC3HAV1L	Zinc finger CCCH-type antiviral protein 1-like	0.964	landscape →
Q8IYL2	—	0.964	Q8IYL2 →
Q99LG4	—	0.964	Q99LG4 →
Q5PPG7	—	0.964	Q5PPG7 →
Q96NW4	—	0.963	Q96NW4 →
Q7TPQ3	—	0.963	Q7TPQ3 →
PARP3	Protein mono-ADP-ribosyltransferase PARP3	0.963	landscape →
A5PK19	—	0.963	A5PK19 →
EIF2B5	Translation initiation factor eIF2B subunit epsilon	0.963	landscape →
O94941	—	0.963	O94941 →
Q9NVU0	—	0.963	Q9NVU0 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.963	landscape →
Q496Y0	—	0.963	Q496Y0 →
F1ND48	—	0.963	F1ND48 →
Q0GNC1	—	0.963	Q0GNC1 →